WILMINGTON, Mass., Sept. 9, 2014 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB: IMSC), a high technology supplier of
systems and sensors for homeland security and defense markets,
announced today it has sold 12 QS-B220 desktop explosives and drugs
trace detectors to Incheon International Airport Corporation,
operator of Incheon International Airport, the largest airport in
South Korea. Implant Sciences'
ETDs will be deployed for airport security and will replace
existing systems the airport had in place from a competitor.
"This customer was looking to replace a competing installed
product with a more cost-efficient, high-performance ETD from a
company that provides superior customer service and support,"
stated Dr. Darryl Jones, Implant
Sciences' Vice President of Global Sales and Marketing. "This
airport had been evaluating our QS-B220, but the sale was
contingent upon our system being added to the TSA's Qualified
Products List. Upon being placed on the TSA's QPL, the customer
immediately placed their order."
"At Implant Sciences, our commitment to a culture of service is
a priority and we believe it differentiates us in the market. Our
local distributor, A&T, has a strong track record, is one of
the most active leaders of the security market in South Korea, and will provide service and
support to Incheon International Airport. We are pleased to work
with them," Jones added.
About the QS-B220 Desktop Explosives and Drugs Trace
Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly
detect and identify trace amounts of a wide variety of military,
commercial, and homemade explosives as well as illicit drugs. With
significantly lower maintenance requirements than competing
systems, the QS-B220 can be deployed for a much lower total cost of
ownership than other approved products. Featuring a radioactive
material-free design, push-button maintenance and diagnostics, and
a patented inCalâ„¢ internal automatic calibration system, the
QS-B220 brings new levels of performance and convenience to desktop
trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. Implant
Sciences is only the third manufacturer, and the sole
American-owned company, to currently have an ETD system named as a
Qualified Product by the U.S. Transportation Security
Administration. The Company's ETDs have received approvals and
certifications from several international regulatory agencies
including the TSA in the U.S., STAC in France, the German Ministry of the Interior,
and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland
Security Award for "Best Explosives Detection Solution". All
Implant Sciences products are recognized as Qualified
Anti-Terrorism Technologies by the Department of Homeland Security.
For further details on the Company and its products, please visit
the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995. Such statements are based on
management's current expectations and are subject to risks and
uncertainties that could cause the Company's actual results to
differ materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
there is no guaranty that the Transportation Security
Administration (TSA) or any other U.S. or foreign government and
law enforcement agencies or commercial consumers will purchase any
of our explosives detection products or that any new products we
may develop will be accepted by the TSA or by such other
governments, agencies or consumers; economic, political and other
risks associated with international sales and operations could
adversely affect our sales; our business is subject to intense
competition and rapid technological change, and our success will
depend on our ability to develop and introduce new products; and
other risks and uncertainties described in our filings with the
Securities and Exchange Commission, including our most recent Forms
10-K, 10-Q and 8-K. Such statements are based on management's
current expectations and assumptions which could differ materially
from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
SOURCE Implant Sciences Corporation